Additional Supporting Information may be found in the online version of this article.

pbc25081-sm-0001-SuppFigLeg-S1.docx14KSupplemental Figure Legends.
pbc25081-sm-0001-SuppFig-S1.tif4179KFig. S1 MK-1775 effects on cell cycle, mitosis, and DNA damage.
pbc25081-sm-0001-SuppFig-S2.tif4973KFig. S2 MK-1775 can decrease G2/M fraction of viable CMY cells, especially at higher doses.
pbc25081-sm-0001-SuppFig-S3.tif6679KFig. S3 CMK cells treated with the combination of AraC and lower doses of MK-1775 appear to die out of S-phase.
pbc25081-sm-0001-SuppTab-S1.docx14KTable S1 3-Day IC50s in CMK and CMY

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.